Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Pharmacogenomics (London)

• Publication date

  2015-06-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/pgs.15.46PMID 26115084
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel

  2014cited by this paper
• Whole-Exome Sequencing Reveals Defective CYP3A4 Variants Predictive of Paclitaxel Dose-Limiting Neuropathy

  2014cited by this paper
• Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy

  2014cited by this paper
• Defining Risks of Taxane Neuropathy: Insights from Randomized Clinical Trials

  2013cited by this paper
• CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity

  2013cited by this paper
• CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes.

  2013cited by this paper
• Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro

  2013cited by this paper
• CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel.

  2013cited by this paper
• Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer.

  2012cited by this paper
• CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel

  2012cited by this paper
• Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer

  2011cited by this paper
• Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer

  2011cited by this paper
• Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity

  2011cited by this paper
• Pharmacogenomic biomarkers: new tools in current and future drug therapy.

  2011cited by this paper
• Taxanes: promising anti-cancer drugs.

  2011cited by this paper
• Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5.

  2011cited by this paper
• A method and server for predicting damaging missense mutations

  2010cited by this paper
• Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug–drug interactions

  2010cited by this paper
• The ABCB1 3435 T allele does not increase the risk of paclitaxel-induced neurotoxicity.

  2010cited by this paper
• Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer.

  2009cited by this paper
• Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers

  2008cited by this paper
• Overview of the pharmacogenomics of cigarette smoking

  2007cited by this paper
• CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population

  2007cited by this paper
• Amodiaquine Metabolism is Impaired by Common Polymorphisms in CYP2C8: Implications for Malaria Treatment in Africa

  2007cited by this paper
• Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.

  2007cited by this paper
• ERp29, an Unusual Redox-Inactive Member of the Thioredoxin Family

  2006cited by this paper
• Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype

  2006cited by this paper
• Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 Polymorphisms with the Pharmacokinetics of Paclitaxel

  2005cited by this paper
• SIFT: predicting amino acid changes that affect protein function

  2003cited by this paper
• Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism.

  2001cited by this paper
• Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.

  2001cited by this paper
• The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents.

  1997cited by this paper
• A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function.

  1997cited by this paper
• Paclitaxel-induced neuropathy.

  1995cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper

• Review of the Contribution of Clinical and Genetic Factors to the Racial Disparity in Taxane-Induced Peripheral Neuropathy.

  2025cites this paper
• Genetic determinants of paclitaxel-induced peripheral neuropathy: a review of current literature

  2025cites this paper
• Meta-analysis of the global distribution of clinically relevant CYP2C8 alleles and their inferred functional consequences

  2024cites this paper
• Cytochrome P450 oxidoreductase, POR, associated with severe paclitaxel-induced peripheral neuropathy in patients of European ancestry from ECOG-ACRIN E5103.

  2023cites this paper
• Role of Genetic Polymorphisms in Drug-Metabolizing Enzyme-Mediated Toxicity and Pharmacokinetic Resistance to Anti-Cancer Agents: A Review on the Pharmacogenomics Aspect

  2022cites this paper
• Management of Side Effects in the Personalized Medicine Era: Chemotherapy-Induced Peripheral Neurotoxicity.

  2022cites this paper
• Pharmacogenetics of taxane‐induced neurotoxicity in breast cancer: Systematic review and meta‐analysis

  2022cites this paper
• Drug metabolism and pharmacokinetic diversity of Taxus medicinal compounds

  2021cites this paper
• Breast cancer: Muscarinic receptors as new targets for tumor therapy

  2021cites this paper
• Challenges to assess substrate-dependent allelic effects in CYP450 enzymes and the potential clinical implications

  2019cites this paper
• Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure.

  2019cites this paper
• A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer.

  2019cites this paper
• Impact of gene polymorphisms on the systemic toxicity to paclitaxel/carboplatin chemotherapy for treatment of gynecologic cancers

  2019cites this paper
• Pathogenesis of paclitaxel-induced peripheral neuropathy: A current review of in vitro and in vivo findings using rodent and human model systems.

  2019cites this paper
• Induction of Amodiaquine Metabolism by Rifampicin Following Concurrent Administration in Healthy Volunteers

  2018cites this paper
• Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism.

  2017cites this paper
• Comparison of the in vitro metabolism of psoralidin among different species and characterization of its inhibitory effect against UDP- glucuronosyltransferase (UGT) or cytochrome p450 (CYP450) enzymes.

  2016cites this paper
• Targeted Sequencing Reveals Low-Frequency Variants in EPHA Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy

  2016cites this paper
• Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients

  2016cites this paper
• Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions

  2016cites this paper
• GENETIC VARIANTS AND PACLITAXEL TOXICITY 123 6

  2016cites this paper